Back to top

biotechnology: Archive

Zacks Equity Research

Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates

Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.

REGNNegative Net Change GILDNegative Net Change VYGRPositive Net Change OCGNPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates

Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.

DVAXNegative Net Change ENDPPositive Net Change VRTXNegative Net Change AXSMNegative Net Change

Zacks Equity Research

New Strong Sell Stocks for March 1st

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

ALIMPositive Net Change AGIONegative Net Change BVPositive Net Change

Zacks Equity Research

Best Income Stocks to Buy for March 1st

GOGL, ESALY, and ADM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2022

ADMNegative Net Change ESALYPositive Net Change

Zacks Equity Research

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

GSKNegative Net Change GILDNegative Net Change VRTXNegative Net Change VIRNegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp

Teladoc Health, Albireo Pharma and The Joint Corp are included in this blog.

TDOCNegative Net Change JYNTNegative Net Change ALBOPositive Net Change

Zacks Equity Research

Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong

Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.

BMYNegative Net Change PFENegative Net Change MRKNegative Net Change EXELNegative Net Change

Zacks Equity Research

Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

RHHBYNegative Net Change BMYNegative Net Change NVOPositive Net Change PRTANegative Net Change

Sweta Killa

Top and Flop ETFs At Midway Q1

We have highlighted the five best-performing zones and their ETFs halfway through first-quarter 2022.

BBCNegative Net Change OIHPositive Net Change ARKKNegative Net Change PALLPositive Net Change BDRYNegative Net Change PFIXNegative Net Change

Zacks Equity Research

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

GILDNegative Net Change IMGNPositive Net Change BDSIPositive Net Change SGENPositive Net Change COLLNegative Net Change

Zacks Equity Research

Will Dynavax's (DVAX) Growth Momentum Continue in 2022?

Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.

DVAXNegative Net Change VRTXNegative Net Change VIRNegative Net Change VALNPositive Net Change

Zacks Equity Research

New Strong Sell Stocks for February 15th

ATGE, ALGN, and APDN have been added to the Zacks Rank #5 (Strong Sell) List on February 15, 2022

ALGNNegative Net Change APDNPositive Net Change ATGENegative Net Change